205 related articles for article (PubMed ID: 21599008)
1. Comparison of active and passive targeting of docetaxel for prostate cancer therapy by HPMA copolymer-RGDfK conjugates.
Ray A; Larson N; Pike DB; Grüner M; Naik S; Bauer H; Malugin A; Greish K; Ghandehari H
Mol Pharm; 2011 Aug; 8(4):1090-9. PubMed ID: 21599008
[TBL] [Abstract][Full Text] [Related]
2. Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancer.
Peng ZH; Sima M; Salama ME; Kopečková P; Kopeček J
J Drug Target; 2013 Dec; 21(10):968-80. PubMed ID: 24160903
[TBL] [Abstract][Full Text] [Related]
3. Biodistribution of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer drug delivery.
Borgman MP; Aras O; Geyser-Stoops S; Sausville EA; Ghandehari H
Mol Pharm; 2009; 6(6):1836-47. PubMed ID: 19743884
[TBL] [Abstract][Full Text] [Related]
4. Targetable HPMA copolymer-aminohexylgeldanamycin conjugates for prostate cancer therapy.
Borgman MP; Ray A; Kolhatkar RB; Sausville EA; Burger AM; Ghandehari H
Pharm Res; 2009 Jun; 26(6):1407-18. PubMed ID: 19225872
[TBL] [Abstract][Full Text] [Related]
5. Prostate-cancer-targeted N-(2-hydroxypropyl)methacrylamide copolymer/docetaxel conjugates.
Liu J; Kopečková P; Pan H; Sima M; Bühler P; Wolf P; Elsässer-Beile U; Kopeček J
Macromol Biosci; 2012 Mar; 12(3):412-22. PubMed ID: 22493797
[TBL] [Abstract][Full Text] [Related]
6. HPMA copolymer-based combination therapy toxic to both prostate cancer stem/progenitor cells and differentiated cells induces durable anti-tumor effects.
Zhou Y; Yang J; Rhim JS; Kopeček J
J Control Release; 2013 Dec; 172(3):946-53. PubMed ID: 24041709
[TBL] [Abstract][Full Text] [Related]
7. Synergistic enhancement of cancer therapy using a combination of heat shock protein targeted HPMA copolymer-drug conjugates and gold nanorod induced hyperthermia.
Larson N; Gormley A; Frazier N; Ghandehari H
J Control Release; 2013 Aug; 170(1):41-50. PubMed ID: 23602864
[TBL] [Abstract][Full Text] [Related]
8. The structure of polymer carriers controls the efficacy of the experimental combination treatment of tumors with HPMA copolymer conjugates carrying doxorubicin and docetaxel.
Šírová M; Strohalm J; Chytil P; Lidický O; Tomala J; Říhová B; Etrych T
J Control Release; 2017 Jan; 246():1-11. PubMed ID: 27940304
[TBL] [Abstract][Full Text] [Related]
9. In vitro synergistic action of geldanamycin- and docetaxel-containing HPMA copolymer-RGDfK conjugates against ovarian cancer.
Larson N; Roberts S; Ray A; Buckway B; Cheney DL; Ghandehari H
Macromol Biosci; 2014 Dec; 14(12):1735-47. PubMed ID: 25185891
[TBL] [Abstract][Full Text] [Related]
10. HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release.
Etrych T; Sírová M; Starovoytova L; Ríhová B; Ulbrich K
Mol Pharm; 2010 Aug; 7(4):1015-26. PubMed ID: 20518512
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy of prostate cancer with HPMA copolymer conjugates containing PI3K/mTOR inhibitor and docetaxel.
Zhou Y; Yang J; Zhang R; Kopeček J
Eur J Pharm Biopharm; 2015 Jan; 89():107-15. PubMed ID: 25481033
[TBL] [Abstract][Full Text] [Related]
12. Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect.
Kovár M; Strohalm J; Etrych T; Ulbrich K; Ríhová B
Bioconjug Chem; 2002; 13(2):206-15. PubMed ID: 11906257
[TBL] [Abstract][Full Text] [Related]
13. Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates.
Line BR; Mitra A; Nan A; Ghandehari H
J Nucl Med; 2005 Sep; 46(9):1552-60. PubMed ID: 16157540
[TBL] [Abstract][Full Text] [Related]
14. HPMA copolymer-cyclic RGD conjugates for tumor targeting.
Pike DB; Ghandehari H
Adv Drug Deliv Rev; 2010 Feb; 62(2):167-83. PubMed ID: 19951733
[TBL] [Abstract][Full Text] [Related]
15. Anticancer and antiangiogenic activity of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer therapy.
Greish K; Ray A; Bauer H; Larson N; Malugin A; Pike D; Haider M; Ghandehari H
J Control Release; 2011 May; 151(3):263-70. PubMed ID: 21223983
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of N-(2-hydroxypropyl) methacrylamide copolymer-Mesochlorine e6 and adriamycin conjugates in combination treatments.
Shiah JG; Sun Y; Peterson CM; Straight RC; Kopecek J
Clin Cancer Res; 2000 Mar; 6(3):1008-15. PubMed ID: 10741728
[TBL] [Abstract][Full Text] [Related]
17. Tumor-targeted HPMA copolymer-(RGDfK)-(CHX-A''-DTPA) conjugates show increased kidney accumulation.
Borgman MP; Coleman T; Kolhatkar RB; Geyser-Stoops S; Line BR; Ghandehari H
J Control Release; 2008 Dec; 132(3):193-9. PubMed ID: 18687371
[TBL] [Abstract][Full Text] [Related]
18. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.
Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H
Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482
[TBL] [Abstract][Full Text] [Related]
19. Gold nanorod-mediated hyperthermia enhances the efficacy of HPMA copolymer-90Y conjugates in treatment of prostate tumors.
Buckway B; Frazier N; Gormley AJ; Ray A; Ghandehari H
Nucl Med Biol; 2014 Mar; 41(3):282-9. PubMed ID: 24461626
[TBL] [Abstract][Full Text] [Related]
20. Tumor targeting by pH-sensitive, biodegradable, cross-linked N-(2-hydroxypropyl) methacrylamide copolymer micelles.
Zhou Z; Li L; Yang Y; Xu X; Huang Y
Biomaterials; 2014 Aug; 35(24):6622-35. PubMed ID: 24814427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
